The role of the NFκB signalling pathway in cancer

被引:42
作者
Cortes Sempere, Maria [1 ]
Rodriguez Fanjul, Vanesa [1 ]
Sanchez Perez, Isabel [1 ]
Perona, Rosario [1 ]
机构
[1] Inst Invest Biomed CSIC UAM, Translat Oncol Unit, Ctr Invest Biomed Red Enfermedades Raras, ES-28029 Madrid, Spain
关键词
rel; NF kappa B; I kappa B; bortezomib; IKK;
D O I
10.1007/s12094-008-0171-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The nuclear factor kappa B (NF kappa B) signalling pathway regulates the expression of hundreds of genes that are involved in different cellular processes such as cell proliferation, survival, stress responses, cellular immunity and inflammation. Its aberrant regulation is involved in several pathologies, but its relevance in cellular transformation and cancer development has been extensively studied. Mutations in the core components of NF kappa B as well as in the cellular machinery that regulates its activation have been found in many types of tumours. On the other hand, its role in promoting cell survival is an important obstacle in many cancer therapies. The development of chemical inhibitors that block NF kappa B activation acting either directly on IKKs or on the proteosome machinery has shown antitumour and proapoptotic activity both in preclinical and clinical studies.
引用
收藏
页码:143 / 147
页数:5
相关论文
共 28 条
[1]   Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract [J].
Barth, TFE ;
Bentz, M ;
Leithäuser, F ;
Stilgenbauer, S ;
Siebert, R ;
Schlotter, M ;
Schlenk, RF ;
Döhner, H ;
Möller, P .
GENES CHROMOSOMES & CANCER, 2001, 31 (04) :316-325
[2]   The two NF-κB activation pathways and their role in innate and adaptive immunity [J].
Bonizzi, G ;
Karin, M .
TRENDS IN IMMUNOLOGY, 2004, 25 (06) :280-288
[3]   THE ONCOPROTEIN BCL-3 DIRECTLY TRANSACTIVATES THROUGH KAPPA-B MOTIFS VIA ASSOCIATION WITH DNA-BINDING P50B HOMODIMERS [J].
BOURS, V ;
FRANZOSO, G ;
AZARENKO, V ;
PARK, S ;
KANNO, T ;
BROWN, K ;
SIEBENLIST, U .
CELL, 1993, 72 (05) :729-739
[4]   The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-xL [J].
Chen, CL ;
Edelstein, LC ;
Gélinas, C .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (08) :2687-2695
[5]   The NF-κB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance [J].
Cilloni, D ;
Messa, F ;
Arruga, F ;
Defilippi, I ;
Morotti, A ;
Messa, E ;
Carturan, S ;
Giugliano, E ;
Pautasso, M ;
Bracco, E ;
Rosso, V ;
Sen, A ;
Martinelli, G ;
Baccarani, M ;
Saglio, G .
LEUKEMIA, 2006, 20 (01) :61-67
[6]   The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: A california cancer consortium phase I study [J].
Davies, Angela M. ;
Ruel, Christopher ;
Lara, Primo N. ;
Lau, Derick H. ;
Gumerlock, Paul H. ;
Bold, Richard ;
Shibata, Stephen ;
Lenz, Heinz-Josef ;
Schenkein, David P. ;
Gandara, Anddavid R. .
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (01) :68-74
[7]   Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer [J].
Davies, Angela M. ;
Ho, Cheryl ;
Metzger, Alex S. ;
Beckett, Laurel A. ;
Christensen, Scott ;
Tanaka, Michael ;
Lara, Primo N. ;
Lau, Derick H. ;
Gandara, David R. .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (12) :1112-1116
[8]   Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study [J].
Davis, NB ;
Taber, DA ;
Ansari, RH ;
Ryan, CW ;
George, C ;
Vokes, EE ;
Vogelzang, NJ ;
Stadler, WM .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :115-119
[9]   Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma [J].
Fukuhara, Noriko ;
Tagawa, Hiroyuki ;
Kameoka, Yoshihiro ;
Kasugai, Yumiko ;
Karnan, Sivasundaram ;
Kameoka, Junichi ;
Sasaki, Takeshi ;
Morishima, Yasuo ;
Nakamura, Shigeo ;
Seto, Masao .
CANCER SCIENCE, 2006, 97 (06) :499-504
[10]  
Guttridge DC, 1999, MOL CELL BIOL, V19, P5785